Bio-Path Holdings (BPTH) AI Stock Analysis

• Market Cap: $536.04K
• Dividend Yield: N/A
• Average Volume (3M): 24.92K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.32
• Revenue Growth: N/A
• EPS Growth: 88.04%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 9,242,151
• 10 Day Avg. Volume: 24,655
• 30 Day Avg. Volume: 24,916
• PEG Ratio: <0.01
• Price to Book (P/B): 18.09
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.26
• Enterprise Value/Market Cap: 1.89
• Enterprise Value/Revenue: 6.42
• Enterprise Value/Gross Profit: 169.17
• Enterprise Value/Ebitda: -0.09
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.05 ▲(8.00% Upside)

The score is driven primarily by very weak financial performance (no revenue, sustained losses and cash burn, and sharply depleted equity), implying high financing dependence. Technicals remain bearish with the price below major moving averages, and valuation provides little support given ongoing losses and no dividend. A negative corporate development—seeking financing with acknowledged listing/continuity risks—adds further downside risk.

Positive Factors

Proprietary Delivery Platform

A proprietary delivery platform is a durable competitive asset in oligonucleotide therapeutics where delivery is a key technical barrier. DNAbilize can enable multiple programs, reduce trial failure risk from delivery issues, and improve partnerability and long-term program scalability.

Oncology-Focused Pipeline (AML)

Concentrated focus on oncology, especially AML, targets structurally large unmet medical need and sustained commercial demand. Success in these indications creates durable value through high pricing potential, repeatable clinical pathways, and attractiveness to strategic partners or acquirers.

Low Absolute Debt Burden

Minimal nominal debt reduces interest and covenant pressures, preserving operational flexibility. With low interest burden the company can prioritize R&D or strategic transactions; this provides some runway advantage relative to highly leveraged peers despite other capital constraints.

Negative Factors

No Product Revenue

Absence of product revenue means the business cannot self-fund development; persistent operating losses force reliance on external capital or partnerships. This structural lack of internal cash generation increases execution risk and makes long-term viability contingent on financing outcomes.

Severe Equity Erosion

Dramatic depletion of equity materially weakens the company’s capital cushion, reducing its ability to absorb further losses or fund trials internally. This elevates refinancing and dilution risk, constrains borrowing capacity, and increases the probability of distressed transactions over the coming months.

Financing & Listing Risk

Active efforts to raise capital, hire new auditors, and engage bankers represent a structural shift toward funding-dependent restructuring. This heightens dilution, potential divestitures, and continuity/listing risk, creating strategic uncertainty that can delay R&D timelines and partner negotiations.

Bio-Path Holdings Business Overview & Revenue Model

Company Description

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

How the Company Makes Money

Bio-Path Holdings makes money primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model includes licensing agreements, partnerships with larger pharmaceutical firms, and potential future sales of approved drugs. Bio-Path may also receive milestone payments and royalties from these partnerships and collaborations as their drug candidates advance through clinical trials and, if successful, reach the market. Additionally, the company might engage in raising capital through stock offerings to fund its research and development efforts.

Bio-Path Holdings Financial Statement Overview

Summary

Very weak fundamentals: revenue is $0 across reported years with persistent large operating and net losses. Equity has eroded sharply (to about $0.15M in 2024), leaving a limited capital buffer, while operating and free cash flow remain meaningfully negative, indicating ongoing dependence on external financing.

Income Statement

Financial performance remains weak: revenue is $0 across all reported years, with consistently negative gross profit and large operating losses. Net losses widened materially in 2023 (net loss of ~$16.1M) before improving in 2024 (net loss of ~$9.9M), but the business is still far from profitability and has not demonstrated a revenue ramp.

Balance Sheet

Leverage is low in absolute dollars (2024 total debt of ~$0.08M), but the balance sheet has deteriorated sharply as equity fell from ~$25.5M (2021) to ~$0.15M (2024), indicating heavy cumulative losses and reduced capital cushion. With equity now very small, the debt-to-equity ratio has risen (to ~0.54 in 2024) and returns on equity are deeply negative, increasing financial risk despite modest debt levels.

Cash Flow

Cash burn is persistent, with negative operating cash flow every year (about -$10.6M in 2024 versus -$11.5M in 2023), showing ongoing funding needs. Free cash flow remains meaningfully negative (roughly -$10.6M in 2024), though the pace of burn improved versus prior years—still, cash generation has not turned the corner.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	158.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	6.00K	-159.00K	-178.00K	-178.00K	-161.00K	-151.00K
EBITDA	-10.75M	-9.73M	-15.76M	-13.69M	-10.28M	-10.73M
Net Income	-11.18M	-9.89M	-16.08M	-13.84M	-10.44M	-10.86M
Balance Sheet
Total Assets	690.00K	3.88M	3.22M	15.97M	26.57M	16.48M
Cash, Cash Equivalents and Short-Term Investments	0.00	1.17M	1.05M	10.38M	23.77M	13.76M
Total Debt	479.00K	83.00K	113.00K	221.00K	235.00K	330.00K
Total Liabilities	8.69M	3.73M	2.78M	1.80M	1.11M	1.41M
Stockholders Equity	-8.00M	154.00K	441.00K	14.17M	25.46M	15.07M
Cash Flow
Free Cash Flow	-4.48M	-10.57M	-11.54M	-15.12M	-9.99M	-10.96M
Operating Cash Flow	-4.48M	-10.57M	-11.54M	-15.10M	-9.92M	-10.96M
Investing Cash Flow	0.00	0.00	0.00	-21.00K	-70.00K	0.00
Financing Cash Flow	3.92M	10.70M	2.20M	1.73M	20.01M	4.29M

Bio-Path Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPTH, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.85 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BPTH.

Bio-Path Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCNI	49 Neutral	$835.94K	-0.08	―	―	178.82%	-4121.10%
BPTH	41 Neutral	$536.04K	-0.04	―	―	―	88.04%
BDRX	41 Neutral	$1.10M	-0.03	-60.37%	―	-100.00%	86.75%
OGEN	29 Underperform	$3.50M	-0.05	-168.95%	―	―	90.27%

Bio-Path Holdings Corporate Events

Bio-Path Holdings Seeks Financing for Strategic Turnaround

Bio-Path Holdings is currently seeking financing to support a planned turnaround, which includes updating their finance team, engaging new PCAOB auditors, hiring investment bankers to review their biotech portfolio, and pursuing strategic mergers and acquisitions. The company acknowledges the uncertainty in raising the necessary capital and the potential impact on their ability to continue operations and remain listed on public trading platforms.

The most recent analyst rating on (BPTH) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Bio-Path Holdings stock, see the BPTH Stock Forecast page.